VIZ Plain Royal Blue Adjustable Baseball Cap

Product Information

Your province or territory decides when people receive their doses of the vaccine. These decisions are based on public health recommendations and the latest evidence.

The National Advisory Committee on Immunization (NACI) recommends an mRNA vaccine (Pfizer-BioNTech Comirnaty ® or Moderna Spikevax ®) should be offered for your second dose.

Moderna Spikevax ® Monovalent Omicron COVID-19 vaccine (Omicron XBB.1.5 subvariant) regulatory information The safety and effectiveness of the Moderna Spikevax ® Bivalent COVID-19 vaccine(Original/Omicron BA. 4/5) is based on studies of Spikevax ® Bivalent (Original/Omicron BA.1).

Clinical trials showed that beginning 2 weeks after the second dose, the Moderna Spikevax ® COVID vaccine was:The bivalent Original/Omicron BA.1 0.1 mg/mL multi-dose vial has a royal blue plastic cap and green label. The Moderna Spikevax ® COVID-19 vaccine is approved for primary vaccination in people who are 6 months of age and older. Its safety and effectiveness in people younger than 6 months have not yet been established. This vaccine is also approved as a booster for people 12 years of age and older. Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1) months to 4 years (25 micrograms at least 6 months after their previous dose). If the child has not been previously vaccinated, Spikevax XBB.1.5 should be administered a 2-dose regimen.

Call emergency services if you develop or witness any serious symptoms that could be anallergic reactionafter vaccination. Reporting a possible serious reaction The Moderna Spikevax®Monovalent COVID-19 vaccine(Omicron XBB.1.5 subvariant) is approved for people who are 6 months of age and older. It may be given to people who have been previously vaccinated or who have not been previously vaccinated. After getting vaccinated, it's common to have temporary side effects. These can last a few hours to a few days after vaccination. The Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1) was shown to increase the immune response against the Omicron BA.1 variant. This means that the booster is expected to offer protection against this variant.

Regulation

Health Canada's independent drug review process is recognized around the world for its high standards and rigor. Our decisions are based only on scientific and medical evidence showing that vaccines are safe and effective. The benefits must also outweigh any risks.